We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
RNA category is based on mRNA expression levels in the analyzed samples (RNA assay description). The categories include: tissue/cell line enriched, group enriched, tissue/cell line enhanced, expressed in all, mixed and not detected. RNA category is calculated separately for The Cancer Genome Atlas (TCGA) data from cancer tissues and internally generated Human Protein Atlas (HPA) data from normal tissues and cell lines.
TCGA (cancer tissue):
Expressed in all
HPA (cell line):
Expressed in all
HPA (normal tissue):
Expressed in all
Protein evidencei
Protein evidence scores are generated from several independent sources and are classified as evidence at i) protein level, ii) transcript level, iii) no evidence, or iv) not available.
Evidence at protein level
Protein expression normal tissuei
A summary of the overall protein expression pattern across the analyzed normal tissues. The summary is based on knowledge-based annotation.
"Estimation of protein expression could not be performed. View primary data." is shown for genes analyzed with a knowledge-based approach where available RNA-seq and gene/protein characterization data has been evaluated as not sufficient in combination with immunohistochemistry data to yield a reliable estimation of the protein expression profile.
Standardized explanatory sentences with additional information required for full understanding of the knowledge-based expression profile.
Antibody staining mainly consistent with RNA expression data.
Reliability score - normal tissuesi
Reliability score (score description), divided into Enhanced, Supported, Approved, or Uncertain, is evaluated in normal tissues and based on consistency between antibody staining pattern, available RNA-Seq and gene/protein characterization data, as well as similarity between independent antibodies targeting the same protein.
Kaplan-Meier plots for all cancers where high expression of this gene has significant (p<0.001) association with patient survival are shown in this summary. Whether the prognosis is favourable or unfavourable is indicated in brackets. Each Kaplan-Meier plot is clickable and redirects to a detailed page that includes individual expression and survival data for patients with the selected cancer.
RNA expression overview shows RNA-seq data from The Cancer Genome Atlas (TCGA).
TCGA dataseti
RNA-seq data in 17 cancer types are reported as median FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA). RNA cancer tissue category is calculated based on mRNA expression levels across all 17 cancer tissues and include: cancer tissue enriched, cancer group enriched, cancer tissue enhanced, expressed in all, mixed and not detected. To access cancer specific RNA and prognostic data, click on the cancer name. The cancer types are color-coded according to which type of normal organ the cancer originates from.
Antibody staining in 20 different cancers is summarized by a selection of four standard cancer tissue samples representative of the overall staining pattern. From left: colorectal cancer, breast cancer, prostate cancer and lung cancer. An additional fifth image can be added as a complement. The assay and annotation is described here. Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.
For each cancer, color-coded bars indicate the percentage of patients (maximum 12 patients) with high and medium protein expression level. The cancer types are color-coded according to which type of normal organ the cancer originates from. Low or not detected protein expression results in a white bar. Mouse-over function shows details about expression level and normal tissue of origin. The images and annotations can be accessed by clicking on the cancer name or protein expression bar. If more than one antibody is analyzed, the tabs at the top of the staining summary section can be used to toggle between the different antibodies.
Majority of cancer tissues showed weak to moderate cytoplasmic positivity. Few prostate, lung and pancreatic cancers showed strong immunoreactivity. Lymphomas were mainly negative.
GENE INFORMATIONi
Gene information from Ensembl and Entrez, as well as links to available gene identifiers are displayed here. Information was retrieved from Ensembl if not indicated otherwise.
Gene name
MTOR (HGNC Symbol)
Synonyms
FLJ44809, FRAP, FRAP1, FRAP2, RAFT1, RAPT1
Description
Mechanistic target of rapamycin (HGNC Symbol)
Entrez gene summary
The protein encoded by this gene belongs to a family of phosphatidylinositol kinase-related kinases. These kinases mediate cellular responses to stresses such as DNA damage and nutrient deprivation. This protein acts as the target for the cell-cycle arrest and immunosuppressive effects of the FKBP12-rapamycin complex. The ANGPTL7 gene is located in an intron of this gene. [provided by RefSeq, Sep 2008]
The protein browser displays the antigen location on the target protein(s) and the features of the target protein. The tabs at the top of the protein view section can be used to switch between the different splice variants to which an antigen has been mapped.
At the top of the view, the position of the antigen (identified by the corresponding HPA identifier) is shown as a green bar. A yellow triangle on the bar indicates a <100% sequence identity to the protein target.
Under the antigens, the maximum percent sequence identity of the protein to all other proteins from other human genes is displayed, using a sliding window of 10 aa residues (HsID 10) or 50 aa residues (HsID 50). The region with the lowest possible identity is always selected for antigen design, with a maximum identity of 60% allowed for designing a single-target antigen (read more).
The curve in blue displays the predicted antigenicity i.e. the tendency for different regions of the protein to generate an immune response, with peak regions being predicted to be more antigenic.The curve shows average values based on a sliding window approach using an in-house propensity scale. (read more).
If a signal peptide is predicted by a majority of the signal peptide predictors SPOCTOPUS, SignalP 4.0, and Phobius (turquoise) and/or transmembrane regions (orange) are predicted by MDM, these are displayed.
Low complexity regions are shown in yellow and InterPro regions in green. Common (purple) and unique (grey) regions between different splice variants of the gene are also displayed (read more), and at the bottom of the protein view is the protein scale.
MTOR-001
MTOR-002
MTOR-005
PROTEIN INFORMATIONi
The protein information section displays alternative protein-coding transcripts (splice variants) encoded by this gene according to the Ensembl database.
The ENSP identifier links to the Ensembl website protein summary, while the ENST identifier links to the Ensembl website transcript summary for the selected splice variant. The data in the UniProt column can be expanded to show links to all matching UniProt identifiers for this protein.
The protein classes assigned to this protein are shown if expanding the data in the protein class column. Parent protein classes are in bold font and subclasses are listed under the parent class.
The Gene Ontology terms assigned to this protein are listed if expanding the Gene ontology column. The length of the protein (amino acid residues according to Ensembl), molecular mass (kDalton), predicted signal peptide (according to a majority of the signal peptide predictors SPOCTOPUS, SignalP 4.0, and Phobius) and the number of predicted transmembrane region(s) (according to MDM) are also reported.
Enzymes ENZYME proteins Transferases Kinases Atypical kinases Predicted intracellular proteins Plasma proteins Cancer-related genes Mutated cancer genes Mutational cancer driver genes COSMIC somatic mutations in cancer genes COSMIC Somatic Mutations COSMIC Nonsense Mutations COSMIC Missense Mutations Disease related genes FDA approved drug targets Small molecule drugs Protein evidence (Kim et al 2014) Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000139 [Golgi membrane] GO:0000166 [nucleotide binding] GO:0001030 [RNA polymerase III type 1 promoter DNA binding] GO:0001031 [RNA polymerase III type 2 promoter DNA binding] GO:0001032 [RNA polymerase III type 3 promoter DNA binding] GO:0001156 [TFIIIC-class transcription factor binding] GO:0001932 [regulation of protein phosphorylation] GO:0001933 [negative regulation of protein phosphorylation] GO:0001934 [positive regulation of protein phosphorylation] GO:0001938 [positive regulation of endothelial cell proliferation] GO:0003007 [heart morphogenesis] GO:0003179 [heart valve morphogenesis] GO:0004672 [protein kinase activity] GO:0004674 [protein serine/threonine kinase activity] GO:0005515 [protein binding] GO:0005524 [ATP binding] GO:0005634 [nucleus] GO:0005654 [nucleoplasm] GO:0005737 [cytoplasm] GO:0005739 [mitochondrion] GO:0005741 [mitochondrial outer membrane] GO:0005764 [lysosome] GO:0005765 [lysosomal membrane] GO:0005783 [endoplasmic reticulum] GO:0005789 [endoplasmic reticulum membrane] GO:0005794 [Golgi apparatus] GO:0005829 [cytosol] GO:0005942 [phosphatidylinositol 3-kinase complex] GO:0005979 [regulation of glycogen biosynthetic process] GO:0006109 [regulation of carbohydrate metabolic process] GO:0006112 [energy reserve metabolic process] GO:0006207 ['de novo' pyrimidine nucleobase biosynthetic process] GO:0006468 [protein phosphorylation] GO:0006950 [response to stress] GO:0007050 [cell cycle arrest] GO:0007165 [signal transduction] GO:0007281 [germ cell development] GO:0007420 [brain development] GO:0007569 [cell aging] GO:0007584 [response to nutrient] GO:0007616 [long-term memory] GO:0008542 [visual learning] GO:0009791 [post-embryonic development] GO:0010507 [negative regulation of autophagy] GO:0010592 [positive regulation of lamellipodium assembly] GO:0010628 [positive regulation of gene expression] GO:0010831 [positive regulation of myotube differentiation] GO:0010942 [positive regulation of cell death] GO:0010976 [positive regulation of neuron projection development] GO:0012505 [endomembrane system] GO:0014042 [positive regulation of neuron maturation] GO:0014736 [negative regulation of muscle atrophy] GO:0016020 [membrane] GO:0016049 [cell growth] GO:0016236 [macroautophagy] GO:0016242 [negative regulation of macroautophagy] GO:0016301 [kinase activity] GO:0016310 [phosphorylation] GO:0016605 [PML body] GO:0016740 [transferase activity] GO:0018105 [peptidyl-serine phosphorylation] GO:0018107 [peptidyl-threonine phosphorylation] GO:0019901 [protein kinase binding] GO:0019904 [protein domain specific binding] GO:0021510 [spinal cord development] GO:0030030 [cell projection organization] GO:0030163 [protein catabolic process] GO:0030425 [dendrite] GO:0030838 [positive regulation of actin filament polymerization] GO:0031090 [organelle membrane] GO:0031295 [T cell costimulation] GO:0031397 [negative regulation of protein ubiquitination] GO:0031529 [ruffle organization] GO:0031641 [regulation of myelination] GO:0031669 [cellular response to nutrient levels] GO:0031929 [TOR signaling] GO:0031931 [TORC1 complex] GO:0031932 [TORC2 complex] GO:0031998 [regulation of fatty acid beta-oxidation] GO:0032095 [regulation of response to food] GO:0032868 [response to insulin] GO:0032956 [regulation of actin cytoskeleton organization] GO:0032991 [macromolecular complex] GO:0035176 [social behavior] GO:0035264 [multicellular organism growth] GO:0038202 [TORC1 signaling] GO:0040007 [growth] GO:0042060 [wound healing] GO:0042220 [response to cocaine] GO:0043022 [ribosome binding] GO:0043025 [neuronal cell body] GO:0043087 [regulation of GTPase activity] GO:0043200 [response to amino acid] GO:0043231 [intracellular membrane-bounded organelle] GO:0043276 [anoikis] GO:0043278 [response to morphine] GO:0043610 [regulation of carbohydrate utilization] GO:0044877 [macromolecular complex binding] GO:0045429 [positive regulation of nitric oxide biosynthetic process] GO:0045670 [regulation of osteoclast differentiation] GO:0045727 [positive regulation of translation] GO:0045792 [negative regulation of cell size] GO:0045859 [regulation of protein kinase activity] GO:0045945 [positive regulation of transcription from RNA polymerase III promoter] GO:0046777 [protein autophosphorylation] GO:0046889 [positive regulation of lipid biosynthetic process] GO:0048015 [phosphatidylinositol-mediated signaling] GO:0048255 [mRNA stabilization] GO:0048661 [positive regulation of smooth muscle cell proliferation] GO:0048714 [positive regulation of oligodendrocyte differentiation] GO:0048738 [cardiac muscle tissue development] GO:0050731 [positive regulation of peptidyl-tyrosine phosphorylation] GO:0050769 [positive regulation of neurogenesis] GO:0050882 [voluntary musculoskeletal movement] GO:0051219 [phosphoprotein binding] GO:0051496 [positive regulation of stress fiber assembly] GO:0051534 [negative regulation of NFAT protein import into nucleus] GO:0051896 [regulation of protein kinase B signaling] GO:0051897 [positive regulation of protein kinase B signaling] GO:0055006 [cardiac cell development] GO:0055013 [cardiac muscle cell development] GO:0060048 [cardiac muscle contraction] GO:0060135 [maternal process involved in female pregnancy] GO:0060252 [positive regulation of glial cell proliferation] GO:0060999 [positive regulation of dendritic spine development] GO:0061051 [positive regulation of cell growth involved in cardiac muscle cell development] GO:0071456 [cellular response to hypoxia] GO:0090335 [regulation of brown fat cell differentiation] GO:0090559 [regulation of membrane permeability] GO:1900034 [regulation of cellular response to heat] GO:1901216 [positive regulation of neuron death] GO:1901838 [positive regulation of transcription of nuclear large rRNA transcript from RNA polymerase I promoter] GO:1904000 [positive regulation of eating behavior] GO:1904056 [positive regulation of cholangiocyte proliferation] GO:1904058 [positive regulation of sensory perception of pain] GO:1904193 [negative regulation of cholangiocyte apoptotic process] GO:1904197 [positive regulation of granulosa cell proliferation] GO:1904206 [positive regulation of skeletal muscle hypertrophy] GO:1904213 [negative regulation of iodide transmembrane transport]
Predicted intracellular proteins Cancer-related genes Mutated cancer genes Mutational cancer driver genes COSMIC somatic mutations in cancer genes COSMIC Somatic Mutations COSMIC Nonsense Mutations COSMIC Missense Mutations Protein evidence (Ezkurdia et al 2014)